Schizophrenia Research Forum - A Catalyst for Creative Thinking


Ruaņo G, Goethe JW, Caley C, Woolley S, Holford TR, Kocherla M, Windemuth A, Leon JD. Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients. Mol Psychiatry. 2007 Jan 2 ; Pubmed Abstract

Comments on Related News


Related News: Food for Thought—Weight Gain and Mortality in the Mentally Ill

Comment by:  Mary Reid
Submitted 12 March 2007
Posted 14 March 2007

Atmaca and colleagues report that atypical antipsychotic-, especially clozapine- and olanzapine-induced weight gain is related to increased levels of leptin. How does this tie in with the study by Sangwon Kim and colleagues, who found that clozapine and olanzapine lower levels of active AMPK in mouse hypothalamus tissue while leptin activates hypothalamic AMPK?

Wannamethee et al. conclude, "Plasma leptin is associated with insulin resistance, inflammation, and disturbances in homeostasis independent of waist circumference, suggesting possible pathways by which leptin may influence risk of cardiovascular disease." They also report that leptin is lowered in cigarette smokers.

It is of interest that De Rosa and colleagues report reduced activation of FOXP3 by leptin. Is this a positive or a negative in schizophrenia? Is there a predisposition to develop autoimmune disease with long-term use of these drugs?

View all comments by Mary Reid